Development of primary M, G, and A anti-TNP plaque-forming cell responses in vitro.

PubWeight™: 0.97‹?› | Rank: Top 15%

🔗 View Article (PMID 4576584)

Published in J Immunol on July 01, 1973

Authors

H G Bluestein, C W Pierce

Articles by these authors

Separation of helper T cells from suppressor T cells expressing different Ly components. I. Polyclonal activation: suppressor and helper activities are inherent properties of distinct T-cell subclasses. J Exp Med (1976) 5.66

Genetic control of immune responses in vitro. V. Stimulation of suppressor T cells in nonresponder mice by the terpolymer L-glutamic acid 60-L-alanine 30-L-tyrosine 10 (GAT). J Exp Med (1974) 5.55

Immune responses in vitro. 3. Development of primary gamma-M, gamma-G, and gamma-A plaque-forming cell responses in mouse spleen cell cultures stimulated with heterologous erythrocytes. J Exp Med (1971) 4.89

Immunosuppressive factor(s) extracted from lymphoid cells of nonresponder mice primed with L-glutamic acid60-L-alanine30-L-tyrosine10 (GAT). J Immunol (1976) 3.64

Genetic control of immune responses in vitro. I. Development of primary and secondary plaque-forming cell responses to the random terpolymer 1-glutamic acid 60-1-alanine30-1-tyrosine10 (GAT) by mouse spleen cells in vitro. J Exp Med (1973) 3.55

Biological expressions of lymphocyte activation. II. Generation of a population of thymus-derived suppressor lymphocytes. J Exp Med (1973) 3.50

Biological expressions of lymphocyte activation. 3. Suppression of plaque-forming cell responses in vitro by supernatant fluids from concanavalin A-activated spleen cell cultures. J Immunol (1974) 3.27

Regulation by the H-2 gene complex of macrophage-lymphoid cell interactions in secondary antibody responses in vitro. J Exp Med (1976) 3.10

Genetic control of immune responses in vitro. 3. Tolerogenic properties of the terpolymer L-glutamic acid 60-L-alanine30-L-tyrosine10 (GAT) for spleen cells from nonresponder (H-2s and H-2q) mice. J Exp Med (1974) 3.01

Immune responses in vitro. I. Cellular requirements for the immune response by nonprimed and primed spleen cells in vitro. J Exp Med (1969) 2.84

Genetic control of immune responses in vitro. II. Cellular requirements for the development of primary plaque-forming cell responses to the random terpolymer 1-glutamic acid 60-1-alanine30-1-tyrosine10 (GAT) by mouse spleen cells in vitro. J Exp Med (1973) 2.56

Immune responses in vitro. IV. Suppression of primary M, G, and A plaque-forming cell responses in mouse spleen cell cultures by class-specific antibody to mouse immunoglobulins. J Exp Med (1972) 2.43

Brain-reactive lymphocytotoxic antibodies in the serum of patients with systemic lupus erythematosus. J Clin Invest (1976) 2.20

Use of the monoclonal antibody 12F1 to characterize the differentiation antigen VLA-2. J Immunol (1987) 1.90

Biological expressions of lymphocyte activation : I. Effects of phytomitogens on antibody synthesis in vitro. J Exp Med (1973) 1.83

Cell-mediated immune responses in vitro. I. Suppression of the generation of cytotoxic lymphocytes by concanavalin A and concanavalin A-activated spleen cells. J Exp Med (1974) 1.77

Functional maturation of thymic lymphocyte populations in vitro. J Exp Med (1972) 1.76

Regulation of immune responses by suppressor T cells. Tohoku J Exp Med (1976) 1.73

Genetic control of immune responses in vitro. VI. Experimental conditions for the development of helper T-cell activity specific for the terpolymer L-glutamic aicd60-L-alanine30-L-tyrosine10 (GAT) in nonresponder mice. J Exp Med (1975) 1.70

The stimulation of specific suppressor T cells in genetic non-responder mice by linear random copolymers of L-amino acids. Transplant Rev (1975) 1.64

Specific immune response genes of the guinea pig. I. Dominant genetic control of immune responsiveness to copolymers of L-glutamic acid and L-alanine and L-glutamic acid and L-tyrosine. J Exp Med (1971) 1.64

Analysis of the defects responsible for the impaired regulation of Epstein-Barr virus-induced B cell proliferation by rheumatoid arthritis lymphocytes. I. Diminished gamma interferon production in response to autologous stimulation. J Exp Med (1983) 1.63

Neurocytotoxic antibodies in serum of patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A (1978) 1.57

RNA transcripts for I-J polypeptides are apparently not encoded between the I-A and I-E subregions of the murine major histocompatibility complex. Proc Natl Acad Sci U S A (1983) 1.54

Immune response in vitro: independence of "activated" lymphoid cells. Science (1969) 1.52

Immunosuppressive factor(s) extracted from lymphoid cells of nonresponder mice primed with L-glutamic acid60-L-alanine30-L-tyrosine10 (GAT) II. Cellular source and effect on responder and nonresponder mice. J Exp Med (1977) 1.48

Immune responses in vitro. X. Functions of macrophages. J Immunol (1974) 1.47

Biological expressions of lymphocyte activation. V. Characterization of a soluble immune response suppressor (SIRS) produced by concanavalin A-activated spleen cells. J Immunol (1976) 1.47

Immune responses in vitro. II. Suppression of the immune response in vitro by specific antibody. J Exp Med (1969) 1.45

Impaired regulation of Epstein-Barr virus-induced lymphocyte proliferation in rheumatoid arthritis is due to a T cell defect. J Immunol (1981) 1.44

Immune responses in vitro. V. Suppression of M, G, and A plaque-forming cell responses in cultures of primed mouse spleen cells by class-specific antibody to mouse immunoglobulins. J Exp Med (1972) 1.40

Genetic control of immune responses in vitro. IV. Conditions for cooperative interactions between nonresponder parental B cells and primed (responder plus nonresponder) F1 T cells in the development of an antibody response under Ir gene control in vitro. J Exp Med (1974) 1.40

The immune response suppressed by specific antibody. Immunology (1969) 1.38

Extrathymic T cell maturation. Phenotypic analysis of T cell subsets in nude mice as a function of age. J Immunol (1992) 1.35

Specific immune response genes of the guinea pig. 3. Linkage of the GA and GT immune response genes to histocompatibility genotypes in inbred guinea pigs. J Exp Med (1971) 1.33

T and B cells that recognize the same antigen do not transcribe similar heavy chain variable region gene segments. J Exp Med (1983) 1.31

Platelet glycoproteins Ia, Ic, and IIa are physicochemically indistinguishable from the very late activation antigens adhesion-related proteins of lymphocytes and other cell types. J Clin Invest (1988) 1.31

Altered regulation of Epstein-Barr virus induced lymphoblast proliferation in rheumatoid arthritis lymphoid cells. Arthritis Rheum (1980) 1.31

Mode of action of a soluble immune response suppressor (SIRS) produced by concanavalin a-activated spleen cells. J Immunol (1978) 1.30

Immune responses in vitro. VI. Cell interactions in the development of primary IgM, IgG and IgA plaque-forming cell responses in vitro. Cell Immunol (1973) 1.27

Secondary antibody responses in vitro to L-glutamic acid60-L-alanine30-L-tyrosine10 (GAT) by (responder X nonresponder)F1 spleen cells stimulated by parental GAT-macrophages. J Exp Med (1977) 1.26

Specific immune response genes of the guinea pig. II. Relationship between the poly-L-lysine gene and the genes controlling immune responsiveness to copolymers of L-glutamic acid and L-alanine and L-glutamic acid and L-tyrosine in random-bred Hartley guinea pigs. J Exp Med (1971) 1.25

Vancomycin-induced vasculitis. South Med J (1986) 1.24

Immune responses in vitro. XI. Suppression of primary IgM and IgG plaque-forming cell responses in vitro by alloantisera against leukocyte alloantigens. J Exp Med (1974) 1.24

Site of action of a soluble immune response suppressor (SIRS) produced by concanavalin A-activated spleen cells. J Immunol (1976) 1.21

Histocompatibility specificity. J Exp Med (1971) 1.20

Receptor diversity of insulin-specific T cell lines from C57BL (H-2b) mice. J Immunol (1987) 1.19

Analysis of the defects responsible for the impaired regulation of EBV-induced B cell proliferation by rheumatoid arthritis lymphocytes. II. Role of monocytes and the increased sensitivity of rheumatoid arthritis lymphocytes to prostaglandin E. J Immunol (1983) 1.19

Cerebrospinal fluid antibodies to neuronal cells: association with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med (1981) 1.16

Regulatory mechanisms in immune responses to heterologous insulins. II. Suppressor T cell activation associated with nonresponsiveness in H-2b mice. J Exp Med (1984) 1.12

Regulation of the growth of Epstein-Barr virus-infected B cells. I. Growth regression by E rosetting cells from VCA-positive donors is a combined effect of autologous mixed leukocyte reaction and activation of T8+ memory cells. J Immunol (1985) 1.10

Activation of a suppressor T-cell pathway by interferon. Proc Natl Acad Sci U S A (1982) 1.10

Lymphocyte alteration by procainamide: relation to drug-induced lupus erythematosus syndrome. Lancet (1979) 1.10

Purification and analysis of isoforms of soluble immune response suppressor (SIRS). J Immunol (1985) 1.09

Genetic restriction of macrophage-lymphocyte interactions in secondary antibody responses in vitro. Cold Spring Harb Symp Quant Biol (1977) 1.09

Neuropsychiatric manifestations of systemic lupus erythematosus. N Engl J Med (1987) 1.07

Three T cell hybridomas do not contain detectable heavy chain variable gene transcripts. J Exp Med (1983) 1.06

The pathogenesis of central nervous system manifestations of systemic lupus erythematosus. Arthritis Rheum (1982) 1.06

Modulation of immune responses by suppressor T cells. Fed Proc (1978) 1.05

Soluble immune response suppressor (SIRS) inhibits microtubule function in vivo and microtubule assembly in vitro. J Immunol (1984) 1.04

Antigen-specific suppressor T-cell activity in genetically restricted immune spleen cells. J Exp Med (1978) 1.00

Immunoglobulin receptors on B lymphocytes: shifts in immunoglobulin class during immune responses. Fed Proc (1973) 1.00

Haplotype-specific suppression of antibody responses in vitro. I. Generation of genetically restricted suppressor T cells by neonatal treatment with semiallogeneic spleen cells. J Exp Med (1981) 0.98

Neuropsychiatric disease in Sjögren's syndrome: anti-ribosomal P and anti-neuronal antibodies. Am J Med (1993) 0.98

Mechanism of action of macrophage-derived suppressor factor produced by soluble immune response suppressor-treated macrophages. J Immunol (1981) 0.98

Antigen-specific suppression in genetic responder mice to L-glutamic acid60-L-alanine30-L-tyrosine10 (GAT). Characterization of conventional and hybridoma-derived factors produced by suppressor T cells from mice injected as neonates with syngeneic GAT macrophages. J Exp Med (1982) 0.97

Primary in vitro immunogenicity of liposomal model membranes in mouse spleen cell cultures. J Immunol (1979) 0.97

Neuropsychologic deficits and antineuronal antibodies in pediatric systemic lupus erythematosus. Clin Exp Rheumatol (1990) 0.96

Heterogeneous neurocytotoxic antibodies in systemic lupus erythematosus. Clin Exp Immunol (1979) 0.96

Cell-mediated immune responses in vitro. II. Simultaneous generation of cytotoxic lymphocyte responses to two sets of alloantigens of limited cross-reactivity. J Immunol (1975) 0.96

Suppressor T cells as regulators of lymphocyte functions. Ann N Y Acad Sci (1975) 0.95

Antigen-specific suppressor T cell interactions. II. Characterization of two different types of suppressor T cell factors specific for L-glutamic acid50-L-tyrosine50 (GT) and L-glutamic acid60-L-alanine30-L-tyrosine10 (GAT). J Exp Med (1983) 0.95

Inhibition of interferon or soluble immune response suppressor (SIRS) mediated suppression by levamisole. Int J Immunopharmacol (1983) 0.94

An antigen expressed by avian neuronal cells is also expressed by activated T lymphocytes. Cell Immunol (1992) 0.94

Identification and initial characterization of a nonspecific suppressor factor (macrophage-SF) produced by soluble immune response suppressor (SIRS)-treated macrophages. J Immunol (1981) 0.93

Neoantigen of the membrane attack complex of human complement: Occurrence on peripheral blood leukocytes from patients with systemic lupus erythematosus. Arthritis Rheum (1978) 0.93

BEN, a novel surface molecule of the immunoglobulin superfamily on avian hemopoietic progenitor cells shared with neural cells. Exp Cell Res (1992) 0.93

Conversion of soluble immune response suppressor to macrophage-derived suppressor factor by peroxide. Proc Natl Acad Sci U S A (1981) 0.93

Suppressor T cell activation by human leukocyte interferon. J Immunol (1983) 0.92

Alloantiserum-mediated suppression of histocompatibility-linked Ir-gene-controlled immune responses. Suppressive effects of IgG fragments derived from alloantisera. J Exp Med (1974) 0.92

Very late activation antigens (VLA) are human leukocyte-neuronal crossreactive cell surface antigens. J Exp Med (1986) 0.90

Suppressor T-cell activity in responder X nonresponder (C57BL/10 X DBA/1)F1 spleen cells responsive to L-glutamic acid60-L-alanine30-L-tyrosine10. J Exp Med (1978) 0.90

Lymphocytotoxic antibody activity in cryoprecipitates from serum of patients with SLE. Arthritis Rheum (1976) 0.89

Brain-reactive lymphocytotoxic antibody in the cerebrospinal fluid of patients with systemic lupus erythematosus: correlation with central nervous system involvement. Clin Immunol Immunopathol (1981) 0.89

Cellular requirements for development of primary anti-hapten antibody responses in vitro. J Immunol (1973) 0.89

The effect of epitope density on the in vitro immunogenicity of hapten-sensitized liposomal model membranes. J Immunol (1980) 0.88

Identification and initial characterization of concanavalin A- and interferon-induced human suppressor factors: evidence for a human equivalent of murine soluble immune response suppressor (SIRS). J Immunol (1984) 0.88

Macrophages: modulators of immunity. Parke-Davis Award Lecture. Am J Pathol (1980) 0.88

Haplotype-specific suppression of antibody responses in vitro. II. Suppressor factor produced by T cells and T cell hybridomas from mice treated as neonates with semiallogeneic spleen cells. J Exp Med (1981) 0.87

T cell receptor expression by T cells that mature extrathymically in nude mice. Cell Immunol (1991) 0.87

The biochemistry of antigen-specific T-cell factors. Annu Rev Immunol (1983) 0.87

Lymphocyte reactivity of antisera to cryoproteins in systemic lupus erythematosus. Clin Immunol Immunopathol (1979) 0.87

Sendai virus-specific, H-2-restricted cytotoxic T lymphocyte responses of nude mice grafted with allogeneic or semi-allogeneic thymus glands. J Exp Med (1980) 0.87

Specific immune response genes of the guinea pig. V. Influence of the GA and GT immune response genes on the specificity of cellular and humoral immune responses to a terpolymer of L-glutamic acid, L-alanine, and L-tyrosine. J Exp Med (1972) 0.86

Seryl transfer ribonucleic acid synthetase from bakers' yeast. 3. The seryladenylate-enzyme complex and its interaction with transfer ribonucleic acids. J Biol Chem (1968) 0.86

Purification and initial characterization of the lymphokine soluble immune response suppressor. J Immunol (1983) 0.86

Cell-mediated immune responses in vitro. III. Elimination of specific cytotoxic lymphocyte responses by 3H-thymidine suicide. J Immunol (1975) 0.86

Expression of cell surface antigens by suppressor T cell hybridomas. I. Comparison of phenotype and function. J Immunol (1983) 0.85

The effects of endotoxin on the immune response in the rat. II. Antibodies formed against bovine gamma-globulin in the splenectomized rat. Lab Invest (1967) 0.84